© PR Newswire
06.01.2026
ATOS
LISTED
NASDAQ
Atossa Therapeutics Receives FDA "Study May Proceed" Letter for (Z)-Endoxifen Investigational New Drug Application for Metastatic Breast Cancer
News Preview
SEATTLE, Jan. 6, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company developing innovative medicines for unmet medical needs, today announced that the U.S. Food and Drug Administration ("FDA") issued a "Study May Proceed" letter for the Company's study in metastatic breast cancer which was the...
Themefolio
Profiler
Peergroup
© PR Newswire
06.01.2026
WWH
LISTED
LSE
Worldwide Healthcare Trust PLC - Net Asset Value(s)
News Preview
WORLDWIDE HEALTHCARE TRUST PLC
LEI: 5493003YBCY4W1IMJU04
NET ASSET VALUE
The estimated un-audited net asset val...
Themefolio
Profiler
Peergroup
© PR Newswire
06.01.2026
AMEH
LISTED
NASDAQ
Astrana Health, Inc. to Participate in Upcoming Investor Conference
News Preview
ALHAMBRA, Calif., Jan. 6, 2026 /PRNewswire/ -- Astrana Health, Inc. ("Astrana," and together with its subsidiaries and affiliated entities, the "Company") (NASDAQ: ASTH), a physician-centric, technology-enabled healthcare company empowering providers to deliver accessible, high-quality, and high-value care to all, today announced that leadership i...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© BusinessWire
06.01.2026
BFLY
LISTED
NYSE
Butterfly Network to Extend its Proprietary 3D Imaging Capabilities to Butterfly Garden Developers
News Preview
Butterfly Network, Inc. (NYSE: BFLY) (“Butterfly”, “the company”), a digital health company transforming care with handheld, whole-body ultrasound and intuitive software, today announced plans to release its Beam Steering API for advanced third-party AI application and technology development within the company’s Butterfly Garden™ and Ultrasound-on...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© PR Newswire
06.01.2026
JNJ
LISTED
NYSE
Johnson & Johnson unveils new data showing nipocalimab is the first and only investigational FcRn blocker with potential to reduce systemic lupus erythematosus (SLE) activity in a Phase 2 study
News Preview
The JASMINE study met the primary endpoint and key secondary and exploratory endpoints, including those indicating the potential of nipocalimab for steroid sparingSLE is one of the most prevalent and debilitating autoantibody diseases, causing one's own immune system to mistakenly attack various tissues, which can lead to potentially life-threaten...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.01.2026
DAWN
LISTED
NASDAQ
Day One Completes Acquisition of Mersana Therapeutics
News Preview
Day One Bio today announced the successful close of its acquisition of Mersana Therapeutics, Inc....
Themefolio
Profiler
Peergroup
© PR Newswire
06.01.2026
RNAZ
LISTED
NASDAQ
TransCode Therapeutics Announces Publication of Preclinical Data Supporting Therapeutic Potential of TTX-MC138 in Glioblastoma
News Preview
TTX-MC138 is delivered to glioblastoma tumors in murine models of the disease, following intravenous injectionTTX-MC138 demonstrated suppression of miR-10b target and extended survival in aggressive glioblastoma modelsStudy supports future clinical development of TTX-MC138 for patients with glioblastomaBOSTON, Jan. 6, 2026 /PRNewswire/ -- TransCod...
Themefolio
Profiler
Peergroup
© PR Newswire
06.01.2026
ELAN
LISTED
NYSE
Elanco to Participate in the 44th Annual J.P. Morgan Healthcare Conference
News Preview
INDIANAPOLIS, Jan. 6, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) will participate in the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026. Jeff Simmons, president and CEO, and Bob VanHimbergen, executive vice president and CFO, will represent the company and respond to questions from analysts at 3...
Themefolio
Profiler
Peergroup
© PR Newswire
06.01.2026
EWTX
LISTED
NASDAQ
Edgewise Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026
News Preview
BOULDER, Colo., Jan. 6, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that Kevin Koch, Ph.D., President and Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference....
Themefolio
Profiler
Peergroup
© PR Newswire
06.01.2026
COO
LISTED
NASDAQ
CooperVision to Launch MyDay® MiSight® 1 day Myopia Control Soft Contact Lenses
News Preview
New Lenses Combine Advanced Silicone Hydrogel Material with Proven ActivControl® Technology*1 to Slow the Worsening of Myopia in Children†2,3FAREHAM, England, Jan. 6, 2026 /PRNewswire/ -- CooperVision today announced the forthcoming launch of MyDay® MiSight® 1 day contact lenses in the UK and select European and surrounding markets, expanding its...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.01.2026
MNOV
LISTED
NASDAQ
2026 New Year’s Greetings from the CEO
News Preview
LA JOLLA, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875) provides shareholders a corporate update in the following Letter to Stockholders from CEO Yuichi Iwaki, M.D., Ph.D....
Themefolio
Profiler
Peergroup
© Globe Newswire
06.01.2026
AONC
LISTED
OTC
Lone Star Oncology and American Oncology Network Welcome Dr. Derrick Nguyen
News Preview
American Oncology Network and Lone Star Oncology Welcome Dr. Derrick Nguyen...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© Globe Newswire
06.01.2026
DRTS
LISTED
NASDAQ
Alpha Tau Reports New Positive Results in Two Upcoming Presentations at ASCO GI 2026 Symposium Showcasing Immune-Preservation and High Disease Control in Montreal Pancreatic Cancer Alpha DaRT® Study
News Preview
- Final results from first pancreatic cancer study in Montreal demonstrate 81% disease control rate, or 87% excluding the first two patients -...
Themefolio
Profiler
Peergroup
© Newsfile
06.01.2026
BETR
LISTED
CSE
BetterLife Pharma to Participate in YAFO Capital Access Asia Partnering Forum During JPM Week in San Francisco
News Preview
Vancouver, British Columbia--(Newsfile Corp. - January 6, 2026) - BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) ("BetterLife" or the "Company"), an emerging biopharmaceutical company focused on development of BETR-001, its proprietary non-hallucinogenic derivative of lysergic acid diethylamide ("LSD") for the treatmen...
Themefolio
Profiler
Peergroup
© BusinessWire
06.01.2026
LCTX
LISTED
TLV
Lineage Takes Delivery of Gene-edited Hypoimmune Cell Line Under Partnership With Factor Bioscience
News Preview
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or “off the shelf,” cell therapies for serious medical conditions, today announced the receipt of a novel, induced pluripotent stem cell (iPSC) line containing hypoimmunity edits, from Factor Bioscience Inc. (“Factor”...
Themefolio
Profiler
Peergroup
© BusinessWire
06.01.2026
IMNM
LISTED
NASDAQ
Immunome to Present at 44th Annual J.P. Morgan Healthcare Conference
News Preview
Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Immunome management will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026 at 10:30 a.m. PST.
Interested parties can access a live audio webcast of...
Themefolio
Profiler
Peergroup
© BusinessWire
06.01.2026
TMO
LISTED
NYSE
Thermo Fisher Scientific to Present at the J.P. Morgan 2026 Healthcare Conference
News Preview
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that Marc N. Casper, chairman, president and chief executive officer, will present at the J.P. Morgan 2026 Healthcare Conference on Tuesday, January 13, 2026, at 11:15 a.m. (ET).
A live webcast of the presentation will be available in the Investors section o...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
06.01.2026
ALST
LISTED
OTC
ALST Signs Non-Disclosure Agreement with Major Toronto University for Proposed Allstar Sports Centre Development
News Preview
TORONTO, ON / ACCESS Newswire / January 6, 2026 / ALST is pleased to announce the signing of a Non-Disclosure Agreement (NDA) with a large, internationally recognized university located in Toronto, Ontario, to explore the potential development of an Allstar Sports Centre on approximately 8 acres of land.The NDA establishes a confidential framework...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.01.2026
OTLK
LISTED
NASDAQ
Outlook Therapeutics Appoints Laura Cantrell as Vice President of Corporate Strategy and Business Development
News Preview
ISELIN, N.J., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced it has appointed Laura Cantrell as Vice President of Corporate Strategy and Business Development....
Themefolio
Profiler
Peergroup
© Globe Newswire
06.01.2026
CVRX
LISTED
NASDAQ
CVRx Announces Implementation of New Category I CPT Codes for Barostim Therapy
News Preview
MINNEAPOLIS, Jan. 06, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, confirmed today that Category I Current Procedural Terminology (CPT) codes for baroref...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.01.2026
VCEL
LISTED
NASDAQ
Vericel to Present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026
News Preview
CAMBRIDGE, Mass., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will present at the 44th Annual J.P. Morgan Healthcare Conference at 2:15 p.m. ET (11:15 a.m. PT) on Wednesday, January 14, 2026....
Themefolio
Profiler
Peergroup
© Globe Newswire
06.01.2026
MLSS
LISTED
XASE
Milestone Scientific Launches The Wand® Ambassador Program to Expand Peer Engagement and Accelerate Market Adoption in Dentistry
News Preview
Pilot launched with six registered dental professionals; program expected to scale to 250 ambassadors over 12 months Pilot launched with six registered dental professionals; program expected to scale to 250 ambassadors over 12 months...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.01.2026
LFMD
LISTED
NASDAQ
LifeMD Announces Closing of $50 Million Revolving Credit Facility with Citizens Bank, N.A.
News Preview
NEW YORK, Jan. 06, 2026 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care and pharmacy services, today announced the closing of a new senior secured revolving credit facility (“RCF”) with Citizens Bank, N.A. (“Citizens”). The facility has a maturity date of January 2, 2029 and provides for up to $50 milli...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.01.2026
FBLG
LISTED
NASDAQ
FibroBiologics to Present at 9th Annual BFC Global Healthcare Business Development and Investment Conference
News Preview
HOUSTON, Jan. 06, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics” or the “Company”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced...
Themefolio
Profiler
Peergroup
© BusinessWire
06.01.2026
SMMT
LISTED
NASDAQ
Summit Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
News Preview
Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that it will participate in and present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, California, on Monday, January 12, 2026 at 9:45 AM PT. Robert W. Duggan, Chairman and Co-Chief Executive Officer, and Dr. Maky Zanganeh, President...
Themefolio
Profiler
Peergroup
© BusinessWire
06.01.2026
ARWR
LISTED
NASDAQ
Arrowhead Pharmaceuticals Announces Interim Clinical Data on RNAi-based Obesity Candidates Showing Weight Loss in Obese Patients with Diabetes and Improved Measures of Body Composition
News Preview
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced interim results from two Phase 1/2a clinical trials of ARO-INHBE and ARO-ALK7, the company’s investigational RNA interference (RNAi) therapeutics being developed as potential treatments for obesity. Preliminary results with Arrowhead’s promising new approach to treating obesity and met...
Themefolio
Profiler
Peergroup
© BusinessWire
06.01.2026
ZLAB
LISTED
NASDAQ
Zai Lab Announces National Medical Products Administration (NMPA) Approval of AUGTYRO™ (repotrectinib) for Patients with NTRK-Positive Solid Tumors
News Preview
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that China’s National Medical Products Administration (NMPA) has approved the supplemental New Drug Application (sNDA) for AUGTYRO™ (repotrectinib) for the treatment of adult patients with solid tumors that harbor a neurotrophic tyrosine receptor kinase (NTRK) gene fusion. The approval is...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.01.2026
COEP
LISTED
OTC
Coeptis Therapeutics S-4 Declared Effective by SEC, Proxy Mailing Begins in Anticipation of the Merger Transaction with Z Squared
News Preview
~ Annual/Special Meeting of Shareholders to be Held on January 30, 2026 ~ ~ Annual/Special Meeting of Shareholders to be Held on January 30, 2026 ~...
Themefolio
Profiler
Peergroup
© BusinessWire
06.01.2026
IONS
LISTED
NASDAQ
Ionis to present at 44th Annual J.P. Morgan Healthcare Conference
News Preview
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that Brett P. Monia, Ph.D., chief executive officer, will present a company overview at the 44th Annual J.P. Morgan Healthcare Conference at 8:15 a.m. PT on Tuesday, January 13, 2026.
A live webcast of the presentation can be accessed on the Investors & Media section of the Ionis web...
Themefolio
Profiler
Peergroup
© PR Newswire
06.01.2026
ABBV
LISTED
EURONEXT
MAVIRET® receives Health Canada Approval for the Treatment of Acute Hepatitis C Virus
News Preview
MAVIRET is the first and only oral eight-week pan-genotypic treatment option approved for people with acute or chronic hepatitis C virus (HCV) in CanadaMAVIRET received approval through Health Canada's Priority Review process, based on data from the Phase 3 M20-350 Study establishing it to be a highly efficacious treatment for people with acute he...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.01.2026
STXS
LISTED
XASE
Stereotaxis Receives FDA Approval for MAGiC Ablation Catheter
News Preview
ST. LOUIS, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced it obtained U.S. Food and Drug Administration (FDA) approval for the MAGiC™ Magnetic Interventional Ablation Catheter....
Themefolio
Profiler
Peergroup
© BusinessWire
06.01.2026
VRDN
LISTED
NASDAQ
Viridian Therapeutics Prepares for Transformational 2026
News Preview
Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering, developing and commercializing potential best-in-class medicines for serious and rare diseases, today announces the company’s key priorities and anticipated catalysts for 2026.
“Following another year of strong execution across our portfolio, we enter 202...
Themefolio
Profiler
Peergroup
© PR Newswire
06.01.2026
GNPX
LISTED
NASDAQ
Genprex Announces Positive Preliminary Preclinical Data from Study of GPX-002 in Type 2 Diabetic Animal Studies
News Preview
Preliminary Preclinical Data Demonstrates In Vivo Proof-of-Concept for Novel Diabetes Gene Therapy in Type 2 Diabetic Non-Human PrimatesGPX-002 Rejuvenated Exhausted Beta Cells and Normalized Glucose Levels in Type 2 Diabetic MiceAUSTIN, Texas, Jan. 6, 2026 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.01.2026
COGT
LISTED
NASDAQ
Cogent Biosciences Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference
News Preview
WALTHAM, Mass. and BOULDER, Colo., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that Andrew Robbins, President and Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Confere...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.01.2026
CGON
LISTED
NASDAQ
CG Oncology to Present at the 44th Annual J.P. Morgan Healthcare Conference
News Preview
IRVINE, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced that Arthur Kuan, Chairman & Chief Executive Officer, and Ambaw Bellete...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.01.2026
MDXH
LISTED
NASDAQ
Mdxhealth and University of Oxford to validate GPS test in largest randomized trial of treatment effectiveness in patients with localized prostate cancer
News Preview
Mdxhealth and University of Oxford to validate GPS test in largest randomized trial of treatment effectiveness in patients with localized prostate cancer...
Themefolio
Profiler
Peergroup
© BusinessWire
06.01.2026
ALKS
LISTED
NASDAQ
Alixorexton Granted Breakthrough Therapy Designation by U.S. FDA for the Treatment of Narcolepsy Type 1
News Preview
Alkermes plc (Nasdaq: ALKS) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to alixorexton for the treatment of narcolepsy type 1 (NT1), based on phase 1 and phase 2 clinical data, including positive results from Vibrance-1, a large (n=92) phase 2 study evaluating alixorexton in patient...
Themefolio
Profiler
Peergroup
© BusinessWire
06.01.2026
PODD
LISTED
NASDAQ
Insulet Redefines Diabetes at CES with "Liveable Technology" — A New Frontier in Human-Centered Connected Health
News Preview
Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced its debut at Consumer Electronics Show (CES) 2026, where the Company will showcase its vision for liveable technology through an immersive booth experience, expert panel session, an...
Themefolio
Profiler
Peergroup
© BusinessWire
06.01.2026
NWRN
LISTED
SIX
Newron Further Expands Intellectual Property Portfolio for Evenamide with New EU Composition of Matter Patent
News Preview
Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced that the European Patent Office (EPO) has issued the decision to grant an additional patent covering its lead developmen...
Themefolio
Profiler
Peergroup
© BusinessWire
06.01.2026
PLSE
LISTED
NASDAQ
Pulse Biosciences Selected to Present Late-Breaking Data from the nPulse Cardiac Catheter Study at the AF Symposium
News Preview
Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced that late-breaking data from the nPulse Cardiac Catheter Ablation System first-in-human feasibility study in Europe has been accepted for presentation a...
Themefolio
Profiler
Peergroup
© PR Newswire
06.01.2026
CAH
LISTED
NYSE
Cardinal Health to Announce Second-Quarter Results for Fiscal Year 2026 on February 5
News Preview
DUBLIN, Ohio, Jan. 6, 2026 /PRNewswire/ -- Cardinal Health (NYSE: CAH) plans to release second-quarter financial results for its fiscal year 2026 on February 5, prior to the opening of trading on the New York Stock Exchange. The company will webcast a discussion of these results beginning at 8:30 a.m. Eastern....
Themefolio
Profiler
Peergroup
© Globe Newswire
06.01.2026
SLXN
LISTED
NASDAQ
Silexion Therapeutics Releases CEO Letter to Shareholders Highlighting 2025’s Significant Achievements and Outlining Upcoming Milestones for 2026
News Preview
SIL204 Demonstrated Significant Tumor Inhibition in Positive Pre Clinical Studies with Activity Across Pancreatic, Colorectal, and Lung Cancer Models...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.01.2026
ACRV
LISTED
NASDAQ
Acrivon Therapeutics to Announce Clinical Update on its Ongoing Phase 2b Studies and Planned Confirmatory Phase 3 Trial for ACR-368, Initial Clinical Data on ACR-2316, and Other AP3 Pipeline Updates via Webcast
News Preview
Company to host conference call and webcast at 8:30 a.m. ET on Thursday, January 8, 2026 Company to host conference call and webcast at 8:30 a.m. ET on Thursday, January 8, 2026...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.01.2026
CGTX
LISTED
NASDAQ
Cognition Therapeutics Publishes Phase 2 Clinical Results Showing Zervimesine’s Potential to Slow the Progression of Dementia with Lewy Bodies
News Preview
- Zervimesine exhibited meaningful improvement in behavioral, functional, cognitive, and movement measures compared to placebo - - Zervimesine exhibited meaningful improvement in behavioral, functional, cognitive, and movement measures compared to placebo -...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.01.2026
RGEN
LISTED
NASDAQ
Repligen Executive Chair Tony Hunt to Retire; Dr. Martin D. Madaus Elected Chair
News Preview
WALTHAM, Mass., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that the Board has elected Dr. Martin D. Madaus as Chair of the Board, effective March 13, 2026. As previously communicated1, Tony Hunt is retiring from his role as Executive...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.01.2026
BVS
LISTED
NASDAQ
Bioventus to Present at the 44th Annual J.P. Morgan Healthcare Conference
News Preview
DURHAM, N.C., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS), a global leader in innovations for active healing, today announced that Rob Claypoole, Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026, at 9:45 a.m. PT (12:45 p.m. ET)....
Themefolio
Profiler
Peergroup
© Globe Newswire
06.01.2026
AVXL
LISTED
NASDAQ
Anavex Life Sciences Receives FDA Feedback on Alzheimer’s Disease Program
News Preview
NEW YORK, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, an...
Themefolio
Profiler
Peergroup
© BusinessWire
06.01.2026
CMPS
LISTED
NASDAQ
Compass Pathways Establishes Strategic Collaboration with Radial to Innovate Patient Experience and Inform Potential Delivery Model of COMP360
News Preview
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation announced today it is entering into its seventh strategic collaboration, with Radial Health, Inc., a growing national network of interventional psychiatry practices leveraging technology and operations expertise to opt...
Themefolio
Profiler
Peergroup
© PR Newswire
06.01.2026
BIOA B
LISTED
STO
BLA for subcutaneous formulation of Leqembi® accepted in China
News Preview
STOCKHOLM, Jan. 6, 2026 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that the Biologics License Application (BLA) for the subcutaneous formulation (subcutaneous autoinjector: SC-AI) of Leqembi (lecanemab) for treatment of early Alzheimer's disease has been accepted by the National Medical Products...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.01.2026
SELB
LISTED
NASDAQ
Cartesian Therapeutics Announces New Employment Inducement Grants
News Preview
FREDERICK, Md., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the granting of inducement awards to two new employees. On January 2, 2026, the Company issued to these employees options to purchase...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.01.2026
BCRX
LISTED
NASDAQ
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
RESEARCH TRIANGLE PARK, N.C., Jan. 06, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted one newly-hired employee restricted stock units (RSUs) covering an aggregate of 18,300 shares of BioCryst common stock. The RSUs were granted as of J...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.01.2026
ORKA
LISTED
NASDAQ
Oruka Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
News Preview
MENLO PARK, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis, today announced that the Company will present at the 44th Annual J.P. Morga...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.01.2026
TLRY
LISTED
TSX
Tilray Brands Expands Dry January Offerings with Zero-Proof Spirits, Non-Alcoholic Beers and Hemp-Derived THC Beverages
News Preview
NEW YORK, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. (Nasdaq: TLRY; TSX: TLRY), a global lifestyle and consumer packaged goods company at the forefront of the beverage, cannabis and wellness industries, is redefining what it means to drink mindfully with a collection that blends craft, creativity, and functionality. From hemp-derived d...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.01.2026
MCRB
LISTED
NASDAQ
Seres Therapeutics Announces Publications in Nature Medicine and Journal of Infectious Diseases Highlighting Vowst™ Mechanism of Action and Supporting Broader Live Biotherapeutic Strategy
News Preview
Data demonstrate clinical translation of VOWST mechanisms of action in both first and multiply recurrent CDI patients...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.01.2026
IMAB
LISTED
NASDAQ
NovaBridge Presents Positive Givastomig Dose Expansion Data from the Phase 1b Combination Study in Patients with 1L Metastatic Gastric Cancer
News Preview
ROCKVILLE, Md., Jan. 06, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (NovaBridge or the Company) a global biotechnology platform company committed to accelerating access to innovative medicines, today announced positive updated results from the Phase 1b combination study of givastomig, a Claudin 18.2 (CLDN18.2) x 4-1BB bispecifi...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.01.2026
BCRX
LISTED
NASDAQ
BioCryst to Present at 44th Annual J.P. Morgan Healthcare Conference
News Preview
RESEARCH TRIANGLE PARK, N.C., Jan. 06, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company plans to present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Monday, January 12, 2026, at 1:30 p.m. ET....
Themefolio
Profiler
Peergroup
© Globe Newswire
06.01.2026
AVIR
LISTED
NASDAQ
Atea Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
News Preview
BOSTON, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea, togethe...
Themefolio
Profiler
Peergroup
© Globe Newswire
06.01.2026
LBRX
LISTED
NASDAQ
LB Pharmaceuticals Strengthens Leadership Team with Key Appointments in Corporate Affairs and People & Culture
News Preview
NEW YORK, Jan. 06, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals, Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a clinical-stage biopharmaceutical company developing novel therapies for schizophrenia, bipolar depression, and other neuropsychiatric diseases, today announced the appointments of Ellen Rose as Senior Vice President, Corpo...
Themefolio
Profiler
Peergroup
© Newsfile
06.01.2026
HBFG
LISTED
CSE
Happy Belly Food Group Appoints Former Boston Pizza Vice President of Finance and Business Technology as their Executive Vice President of Finance as Franchising Growth Continues to Accelerate
News Preview
Toronto, Ontario--(Newsfile Corp. - January 6, 2026) - Happy Belly Food Group Inc. (CSE: HBFG) (OTCQB: HBFGF) ("Happy Belly" or the "Company"), a leading consolidator of emerging restaurant brands, is pleased to announce the appointment of Ian Thomas as Executive Vice President of Finance, effective immediately.Mr. Thomas joins Happy Belly with mor...
Themefolio
Profiler
Peergroup
© BusinessWire
06.01.2026
ANGO
LISTED
NASDAQ
AngioDynamics Reports Fiscal Year 2026 Second Quarter Financial Results; Continued Double Digit Med Tech Growth Drives Increased Profitability
News Preview
AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced financial results for the second quarter of fiscal year 2026, which ended November 30, 202...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
